EFA
PROF

Evernest Financial Advisors’s Profound Medical PROF Stock Holding History

Evernest Financial Advisors’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,500
Closed -$205K – 186
2025
Q4 		$205K Buy
+31,500
New +$202K 0.04% 174

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $395M AUM
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Evernest Financial Advisors's PROF Position: Q1 2026 in Review

Evernest Financial Advisors sold out of Profound Medical (PROF) in Q1 2026, closing a stake of 31,500 shares — an estimated $205K sold.

Evernest Financial Advisors first reported a position in PROF in Q4 2025 and held it in 1 quarter. The position peaked at $205K in Q4 2025. 57 funds tracked by Wall St. Rank hold PROF as of Q1 2026.

  • Evernest Financial Advisors reported no remaining Profound Medical position as of Q1 2026 after selling out during the quarter.
  • Evernest Financial Advisors sold 31,500 Profound Medical shares in Q1 2026, an estimated $205K.
  • Evernest Financial Advisors first reported a position in Profound Medical in Q4 2025 and held it in 1 quarter.
  • Evernest Financial Advisors's Profound Medical position peaked at $205K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Profound Medical as of Q1 2026.

Based on Evernest Financial Advisors's 13F filing for Q1 2026, filed 4 May 2026.